MARKET

BCYC

BCYC

Bicycle Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.91
+0.11
+1.04%
Opening 13:18 01/24 EST
OPEN
10.88
PREV CLOSE
10.80
HIGH
11.46
LOW
10.84
VOLUME
10.69K
TURNOVER
--
52 WEEK HIGH
14.91
52 WEEK LOW
6.24
MARKET CAP
47.29M
P/E (TTM)
-5.6896
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BCYC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BCYC News

  • Bicycle Therapeutics collaborates for development BT7401
  • Seeking Alpha - Article.01/07 12:40
  • Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
  • Business Wire.01/07 12:00
  • Is Bicycle Therapeutics plc (BCYC) Going to Burn These Hedge Funds?
  • Insider Monkey.12/22/2019 23:09
  • Bicycle Therapeutics: A Disruptive New Entrant To The Vast Targeted Cancer Treatment Space
  • Seeking Alpha - Article.12/17/2019 20:30

More

Industry

Biotechnology & Medical Research
-2.22%
Pharmaceuticals & Medical Research
-1.63%

Hot Stocks

Name
Price
%Change

About BCYC

Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.
More

Webull offers Bicycle Therapeutics PLC (ADR) (BCYC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.